Furthermore, when combined with renin-angiotensin system blocking agents, the investigators of the PREDIAN (Pentoxifylline for Renoprotection in Diabetic Nephropathy) trial reported it delayed the eGFR loss in stage 3–4 kidney disease in diabetic patients [28,29]. This evidence concerns the gene REN and diabetic kidney disease.